Geospiza Appoints Dr. Bruce Montgomery to its Board of Directors

SEATTLE--(BUSINESS WIRE)-- Geospiza, Inc., the market-leading developer of genetic analysis software, today announced that Dr. Bruce Montgomery was appointed to Geospiza’s Board of Directors. Dr. Montgomery has over 20 years of experience in pharmaceutical and biotechnology management as well as 10 years in academic research and medicine. He recently served as Senior Vice President of Respiratory Therapeutics at Gilead Sciences and was a member of the Gilead Executive Committee. Previously, he had founded and served as Chief Executive Officer of Corus Pharmaceuticals until its sale to Gilead for over $365 million in 2006. Prior to founding Corus, Dr. Montgomery was Executive Vice President of Research & Development for PathoGenesis. Earlier in his career, Dr. Montgomery led new product development at Genentech and taught medicine at the University of California – San Francisco.

"We're fortunate to have Bruce join the board as Geospiza extends its target markets from academic research to pharmaceutical research and development," said Gordon Gardiner, Geospiza’s Chairman. "We expect genetic analysis to become a routine part of drug development and in the future to be the basis of commercial products like diagnostics.” Dr. Montgomery commented, “New genetic sequencing technologies will help us develop a deeper understanding of the complex nature of disease. This knowledge can be applied to improve the outcomes of clinical studies, accelerate drug development and make human healthcare more accurate and cost-effective. Geospiza is at the forefront of this change.”

About Geospiza

Geospiza’s genetic analysis software systems have established an international reputation for usability, reliability and performance since 1997. Geospiza’s products are available on a subscription basis and work out-of-the-box, so that researchers can focus immediately on their science. More information on Geospiza can be found at www.geospiza.com.



CONTACT:

Geospiza, Inc.
Rob Arnold, President, 206-633-4403 x107
[email protected]

KEYWORDS:   United States  North America  Washington

INDUSTRY KEYWORDS:   Technology  Data Management  Software  Health  Genetics  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

In an interview with Israel's Calcalist, Teva CEO Kåre Schultz shared details of his approach to the company's turnaround.

Nerlynx is already struggling in its extended adjuvant breast cancer setting, and new entrants from Daiichi-AZ and SeaGen could pressure it elsewhere.